What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

Autolus secures US$80 million series C funding

UCL Business spinout company, Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced that it closed on a US$80 million (£59 million) Series C financing.

Read More
Featured Technology—

Novel method of analysis of stroke data

Stroke is the leading cause of adult disability in the UK at an estimated cost of £7 billion a year. UCL has developed a system for predicting clinical outcomes so as to provide advance information on the optimum clinical management of each patient.
Read more
Spotlight—

Children are not small adults.

When it comes to the use of medicines, children cannot be treated as small adults.  Find out how our spinout, Therakind, is ensuring that children’s medicine used today is both safe and effective.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

New licensing agreement for UCL technology to combat antimicrobial resistance

/ UCLB News
The alarming rise and spread of antimicrobial resistance is an increasing global challenge and there is considerable interest and an ...

Autolus secures US$80 million series C funding

/ Spinout News
Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs UCL Business spinout company, ...

Synthace raises £7.3m to accelerate biotechnology to enable faster breakthroughs

/ Spinout News
• The Company’s Antha operating system brings end-to-end digitization to biotechnology, replacing current artisanal methods of development • Speaking from ...

Autolus announces initiation of the AMELIA and ALEXANDER studies for AUTO3: phase I/II studies in paediatric ALL and DLBCL

/ Spinout News
AUTO3 is the first dual targeting CAR-T cell therapy to enter clinical studies targeting CD19 and CD22 with independently-acting CARs ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Bringing innovation to life

0
Active spinouts
0
Active licences in 2016
0
Drug discoveries
0
New patent applications